PHAT — PHATHOM PHARMACEUTICALS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying PHAT?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 1 tracked investors who changed their PHAT position last quarter, 0 bought and 1 sold (0% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 57/100 in a Contraction regime).
- +3 tracked investors reported holding PHAT at their latest filing
- +Macro Health is 57/100 in a Contraction regime — historically acceptable for this sectorsource
- −1 tracked investor reduced or exited last quarter (0 reduced, 1 sold out)
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/6/2026.
About PHATHOM PHARMACEUTICALS INC (PHAT)
PHATHOM PHARMACEUTICALS INC (PHAT) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $60M. Across recent filings, tracked investors recorded 1 new positions, 0 increased, 0 reduced, and 1 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in PHAT
How many top investors track PHAT
A small number of top investors own this.
PHAT Ownership Composition
How PHATHOM PHARMACEUTICALS INC is held across tracked investor types, based on reported 13F positions.
- Multi-Strategy / Quant100.0%
Tracked investors currently reporting PHAT
1 tracked investor has since exited this position — listed separately below.
- Izzy EnglanderJun 30, 2026Millennium ManagementShares3.4MValue$36.6M% Portfolio0.01%
- Steve CohenJun 30, 2026Point72 Asset ManagementShares1MValue$11.1M% Portfolio0.01%
- Ken GriffinJun 30, 2026Citadel AdvisorsShares696.8KValue$7.6M% Portfolio0.00%
Previously held PHAT
These investors reported PHAT in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.
| Investor | Firm | Last reported shares | Value then | Last held |
|---|---|---|---|---|
| Paul Tudor Jones | Tudor Investment Corp | 38.2K | $424.7K | Mar 31, 2026 |
Recent activity
- New$8MNov 14, 2024
- Sold$0(-100.00%)Feb 14, 2025
Frequently asked questions
- How many institutional investors hold PHAT?
- 3 tracked institutional investors disclosed a position in PHAT (PHATHOM PHARMACEUTICALS INC) in their most recent 13F filing.
- Who is the largest institutional holder of PHAT?
- Izzy Englander, Millennium Management, holds the largest disclosed position in PHAT, valued at $60M.
- Did institutional ownership of PHAT increase or decrease?
- Across recent 13F filings, tracked investors recorded 1 new positions, 0 increased, 0 reduced, and 1 fully exited PHAT.
- Where does this PHAT ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.